Elsevier

Medical Dosimetry

Volume 38, Issue 4, Winter 2013, Pages 385-389
Medical Dosimetry

Analysis of high–dose rate brachytherapy dose distribution resemblance in CyberKnife hypofractionated treatment plans of localized prostate cancer

https://doi.org/10.1016/j.meddos.2013.04.006Get rights and content

Abstract

The present study is to analyze the CyberKnife hypofractionated dose distribution of localized prostate cancer in terms of high–dose rate (HDR) brachytherapy equivalent doses to assess the degree of HDR brachytherapy resemblance of CyberKnife dose distribution. Thirteen randomly selected localized prostate cancer cases treated using CyberKnife with a dose regimen of 36.25 Gy in 5 fractions were considered. HDR equivalent doses were calculated for 30 Gy in 3 fractions of HDR brachytherapy regimen. The D5% of the target in the CyberKnife hypofractionation was 41.57 ± 2.41 Gy. The corresponding HDR fractionation (3 fractions) equivalent dose was 32.81 ± 1.86 Gy. The mean HDR fractionation equivalent dose, D98%, was 27.93 ± 0.84 Gy. The V100% of the prostate target was 95.57% ± 3.47%. The V100% of the bladder and the rectum were 717.16 and 79.6 mm3, respectively. Analysis of the HDR equivalent dose of CyberKnife dose distribution indicates a comparable resemblance to HDR dose distribution in the peripheral target doses (D98% to D80%) reported in the literature. However, there is a substantial difference observed in the core high-dose regions especially in D10% and D5%. The dose fall-off within the OAR is also superior in reported HDR dose distribution than the HDR equivalent doses of CyberKnife.

Introduction

Generally, the tumor cells have higher α/β than the normal cells. However, cancerous prostate cells are exceptions to this. The α/β value of prostate is between 1.5 Gy and 3 Gy.1, 2, 3, 4 This is lower than the α/β value of surrounding normal cells of the organs at risk (OAR), the bladder and rectum. The α/β value of the rectum for late rectal toxicity is between 3 Gy and 5 Gy.5, 6, 7 Similarly, the α/β of the bladder is estimated as 7 Gy.5 As this low α/β value of the prostatic cancer cells encourages the therapeutic gain factor in hypofractionated radiotherapy, hypofractionation has become a vital fractionation scheme for the treatment of localized prostate cancer. Hypofractionation in prostate has been implemented in many ways. Hypofractionated stereotactic body radiotherapy, hypofractionated high–dose rate (HDR) brachytherapy and hypofractionated intensity-modulated radiotherapy are the few forms of prostate hypofractionation treatment. Prostate brachytherapy has been performed either as low–dose rate, permanent implants with Iodine-125/Palladium-103 seeds8 or as HDR temporary implants9, 10, 11, 12, 13, 14 with Ir-192 sources. The fractionation regimen followed in HDR brachytherapy is an accelerated hypofractionation. Owing to the therapeutic gain advantage, hypofractionation has been implemented in IMRT as well.15 CyberKnife (Accuray Inc., Sunnyvale, CA) is a robotic radiosurgery unit in which most of the treatments are performed in hypofractionation alone. Prostate hypofractionation performed in CyberKnife is a stereotactic body radiotherapy technique. Though the hypofractionation is adopted in several modes, the fractionation regimen followed is not unique. The hypofractionation regimen for CyberKnife is still under research. CyberKnife clinical trials of localized prostate cancer by King et al.16 showed a positive outcome for a fractionation regimen of 36.25 Gy in 5 fractions (7.25 Gy per fraction). Clinical trials by Katz17 showed that the 35 Gy in 5 fractions (7 Gy per fraction) regimen gave better results than the 36.25 Gy in 5 fractions regimen. The fractionation regimens followed in HDR brachytherapy are also not unique. Murali et al.10 followed the protocol of 30 Gy in 3 fractions (10 Gy per fraction) for HDR brachytherapy of localized prostate whereas Martinez et al.11 and Grills et al.12 followed 38 Gy in 4 fractions (9.5 Gy per fraction). Demanes et al.13 followed 2 biologically equivalent fractionation regimens, 42 Gy in 6 fractions and 38 Gy in 4 fractions. The HDR brachytherapy hypofractionation has been accepted as a successful monotherapy mode for localized prostate.11, 12, 13 It is imperative to assess the degree of resemblance of a HDR brachytherapy dose distribution in a CyberKnife hypofractionated dose distribution as the CyberKnife stereotactic radiosurgery for prostate is in forward progression in the modern day radiotherapy. Fuller et al.18 made a trial to create a HDR-like distribution in CyberKnife treatment plan. However, the HDR equivalent dose distributions in CyberKnife treatment plans of prostate cancer have not yet been studied in depth. Sudahar et al.19 analyzed and reported the normalized total dose equivalents of CyberKnife hypofractionated doses of localized prostate cancer. The present study intends to analyze the CyberKnife hypofractionated dose distribution in terms of the accelerated dose regimens of HDR brachytherapy to know the degree of resemblance of CyberKnife dose distribution with the HDR brachytherapy of localized prostate cancer. For this purpose, the HDR fractionation regimen followed by Murali et al.10 was taken as the reference.

Section snippets

Methods and Materials

Thirteen randomly selected localized prostate cancer cases were considered retrospectively for this study. The contouring was done in the dedicated CyberKnife treatment planning system, MultiPlan (Accuray Inc., Sunnyvale, CA). Computed tomography images of 1-mm slice thickness of the pelvic region were acquired and fused with magnetic resonance images to draw the planning target volume (PTV) of the prostate target and the OARs (rectum and bladder). The treatment plans were generated with

CyberKnife hypofractionated dose distribution

The analysis of the target dose distribution in the CyberKnife hypofractionated dose regimen is shown in Table 1. The relative percentages of the target doses are given in Table 2. D98% and D5% are the indicators of the minimum and maximum dose within the target, respectively. The mean values of D98% and D5% were 35.28 ± 1.09 Gy and 41.57 ± 2.41 Gy, respectively. The target conformity, homogeneity indices, and V100% are shown in Table 3. The conformity index was ranging between 1.15 and 1.73,

Discussion

Murali et al.10 compared the dose distribution between IMRT (conventional 2 Gy fractionation) and HDR brachytherapy (30 Gy in 3 fractions). According to that study, the D98% of the PTV is 91.4%. The mean D98% in the present study is 97.34%. It shows a better coverage in CyberKnife plans at 98% coverage level. The HDR doses D90%, D80%, D50%, D10%, and D5% of the PTV reported by Murali et al.10 are 102.4%, 110.7%, 130.6%, 225.5%, and 306.7%, respectively. These volume doses in our present study are

Conclusions

The HDR equivalent doses of CyberKnife hypofractionation show a resemblance with the HDR dose distribution for up to 80% volume doses that are encompassing the prostate target. However, there is an appreciable difference observed in the high-dose regions. The rectum and bladder dose fall-off in CyberKnife are slightly inferior to those of the HDR dose distributions reported in the literature. This study must be extended for further analysis on the same set of patient data to ensure the results

References (23)

  • E. Shaw et al.

    Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines

    Int. J. Radiat. Oncol. Biol. Phys.

    (1993)
  • Cited by (16)

    • Low-cost 3D print–based phantom fabrication to facilitate interstitial prostate brachytherapy training program

      2020, Brachytherapy
      Citation Excerpt :

      Unlike other radiotherapy technologies, brachytherapy delivers the radiation dose directly within the target to give a steep falloff in dose and unrivaled conformity. Attempts to emulate with external beam technology fail to achieve the substantial dose in the immediate vicinity of the source (1,2). Nevertheless, there has been a steady decline in prostate brachytherapy procedures both in academic and community practice (3–6).

    • Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer

      2018, Radiotherapy and Oncology
      Citation Excerpt :

      In this context, the administration of hypofractionated HDR BRT as a boost modality combined with EBRT allows for the safe delivery of high biologically equivalent doses to the prostate, that is not achievable by image-guided EBRT as monotherapy [27–30]. Particularly important in this respect, is the dosimetric superiority of HDR BRT which has proved itself as a high-precision RT method, considered in terms of conformality, comparable to stereotactic approaches [31,32]. Randomised trials as well as mature retrospective data from various institutions corroborate the superiority of combined modalities over EBRT alone in the primary treatment of localised high-risk prostate cancer.

    • Management of local relapse after prostate cancer radiotherapy: Surgery or radiotherapy?

      2017, Cancer/Radiotherapie
      Citation Excerpt :

      This approach could lead to an interesting and new “partial prostate re-irradiation” concept. According to dosimetric and biological considerations, stereotactic radiation therapy represents a new external technique that compares to high dose-rate brachytherapy [41,42]. Very few exploratory studies have been published regarding stereotactic body radiotherapy as a salvage treatment for postradiotherapy recurrences [39,43–45].

    • Iridium-Knife: Another knife in radiation oncology

      2017, Brachytherapy
      Citation Excerpt :

      If this serves as the main argument, then we may plausibly name 3D HDR BRT with iridium-192 (192Ir) the way it would be reasonably justified, namely Iridium-Knife. In this context, several studies assessed the dosimetric differences between 192Ir HDR BRT and SBRT in the treatment of primary and metastatic tumors, showing that HDR BRT achieves higher intratarget doses with a sharper dose falloff outside the target volume and predominantly lower maximum doses to adjacent organs at risk (OARs) compared with SBRT treatment planning (19–26). To add to this experience, we designed a treatment planning study selecting patients we treated with SRS for locally recurrent glioblastoma multiforme (GBM) or with SBRT for intrathoracic malignancies (IM) for comparative 3D interstitial (IRT) 192Ir HDR BRT treatment plan analysis.

    • A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy

      2015, Brachytherapy
      Citation Excerpt :

      There are no prospective clinical comparisons of SBRT vs HDR to date. Most assessments at this time are dosimetric and in general demonstrate that HDR delivers an overall higher dose to the prostate for relatively lower doses to organs at risk compared with SBRT (1–6). Few dosimetry studies have actually tried to reproduce the exact distribution of HDR dose heterogeneity, which is at least partially related to the limited data available on HDR spatial dose distribution.

    View all citing articles on Scopus
    View full text